**PHE publications gateway number: 2018058**

## PATIENT GROUP DIRECTION (PGD)

Administration of meningococcal group B vaccine (rDNA, component, adsorbed) to individuals from 8 weeks of age eligible for the national routine immunisation programme and to individuals for the prevention of secondary cases of meningococcal group B disease.

This PGD is for the administration of meningococcal group B vaccine (rDNA, component, adsorbed) (4CMenB) by registered healthcare practitioners identified in Section 3, subject to any limitations to authorisation detailed in Section 2.

Reference no: MenB PGD

Version no: v03.00

Valid from: 1 May 2018

Review date: 1 November 2019

Expiry date: 30 April 2020

**Public Health England has developed this PGD template to facilitate the delivery of publicly funded immunisations in line with national recommendations.**

Those using this PGD must ensure that it is organisationally authorised and signed in Section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)[[1]](#footnote-2). **THE PGD IS NOT LEGAL OR VALID WITHOUT SIGNED AUTHORISATION IN ACCORDANCE WITH** [**HMR2012 SCHEDULE 16 Part 2**](http://www.legislation.gov.uk/uksi/2012/1916/schedule/16/part/2/made)**.**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition authorising organisations must not alter section 3 ‘Characteristics of staff’. Only sections 2 and 7 can be amended.

Operation of this PGD is the responsibility of commissioners and service providers.

**INDIVIDUAL PRACTITIONERS MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.**

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of PHE PGD templates for authorisation can be found from:

<https://www.gov.uk/government/collections/immunisation>

Any concerns regarding the content of this PGD should be addressed to:

[immunisation@phe.gov.uk](mailto:Immunisation@phe.gov.uk)

# **Change history**

|  |  |  |
| --- | --- | --- |
| **Version number** | **Change details** | **Date** |
| V01.00 | New MenB PHE PGD Template | 21 July 2015 |
| V02.00 | PHE MenB PGD amended to:   * include immunisation into the thigh for individuals over 1 year of age * update dosing recommendations for individuals with incomplete vaccination status * reference the protocol for ordering storage and handling of vaccines * update wording regarding authorisation in line with agreed PHE PGD template changes * include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates | 3 February 2017 |
| V03.00 | PHE MenB PGD amended to:   * update dosing guidance for the prevention of secondary cases of meningococcal group B disease, see Annex A, in line with revised Public Health England [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management) * include additional healthcare practitioners (pharmacists, paramedics, physiotherapists) in Section 3 * refer to the MenB risk groups PGD in the inclusion criteria section * refer to vaccine incident guidelines in off-label and storage sections * include rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates | 24 April 2018 |

1. **PGD template development**

This PGD template has been developed by the following health professionals on behalf of Public Health England:

|  |  |  |  |
| --- | --- | --- | --- |
| **Developed by:** | **Name** | **Signature** | **Date** |
| Pharmacist (Lead Author) | Elizabeth Graham  Lead Pharmacist Immunisation Services, PHE |  | 27/04/2018 |
| Doctor | Mary Ramsay  Consultant Epidemiologist and Head of Immunisation, Hepatitis & Blood Safety Department, PHE |  | 26/04/2018 |
| Registered Nurse (Chair of Expert Panel) | David Green  Nurse Consultant – Immunisations, PHE |  | 26/04/2018 |

This PGD template has been peer reviewed by the PHE Immunisations PGD Expert Panel in accordance with PHE PGD Policy. It has been ratified by the PHE Medicines Management Group and the PHE Quality and Clinical Governance Delivery Board.

**Expert Panel**

|  |  |
| --- | --- |
| **Name** | **Designation** |
| Ed Gardner | Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead |
| Shamez Ladhani | Paediatric Infectious Disease Consultant, Public Health England |
| Jacqueline Lamberty | Lead Pharmacist Medicines Management Services, Public Health England |
| Vanessa MacGregor | Consultant in Communicable Disease Control, Public Health England, East Midlands Health Protection Team |
| Alison Mackenzie | Consultant in Public Health Medicine, Screening and Immunisation Lead, Public Health England / NHS England South (South West) |
| Gill Marsh | Senior Screening and Immunisation Manager Public Health England / NHS England Lancashire and South Cumbria |
| Lesley McFarlane | Screening and Immunisation Co-ordinator (SIC) NHS England Leicestershire, Lincolnshire and Northamptonshire |
| Sally Millership | Consultant in Communicable Disease Control, Public Health England, East of England Health Protection Team |
| Tushar Shah | Pharmacy Advisor, NHS England London Region |
| Kelly Stoker | Senior Health Protection Nurse, North East Health Protection Team, Public Health England Centre North East |
| Sharon Webb | Programme Manager - IDPS , NHS Screening Programmes, Public Health England (Midwife) |
| Helen Wilkinson | Deputy Head of Medicines Management, NHS South Gloucestershire Clinical Commissioning Group |

1. **Organisational authorisations**

The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

INSERT AUTHORISING BODY NAME authorises this PGD for use by the services or providers listed below:

|  |
| --- |
| Authorised for use by the following organisations and/or services |
| eg All NHS England commissioned immunisation services or NHS Trust providing immunisation services. |
| Limitations to authorisation |
| eg Any local limitations the authorising organisation feels they need to apply in-line with the way services are commissioned locally. This organisation does not authorise the use of this PGD by …. |

|  |  |  |  |
| --- | --- | --- | --- |
| Organisational approval (legal requirement) | | | |
| Role | Name | Sign | Date |
| Complete eg NHS England Governance Lead, Medical Director |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Additional signatories according to locally agreed policy | | | |
| Role | Name | Sign | Date |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

Local enquiries regarding the use of this PGD may be directed to…………….

Section 7 provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

#### Characteristics of staff

|  |  |
| --- | --- |
| **Qualifications and professional registration** | Registered professional with one of the following bodies:   * nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) * pharmacists currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to privately provided community pharmacy services) * paramedics and physiotherapists currently registered with Health and Care Professions Council (HCPC)   The practitioners above must also fulfil the [Additional requirements](#StaffAdditionalRequirements) detailed below.  Check [Section 2 Limitations to authorisation](#LimitationsToAuthorisation) to confirm whether all practitioners listed above have organisational authorisation to work under this PGD. |
| **Additional requirements** | Additionally practitioners:   * must be authorised by name as an approved practitioner under the current terms of this PGD before working to it * must have undertaken appropriate training for working under PGDs for supply/administration of medicines * must be competent in the use of PGDs (see [NICE Competency framework](https://www.nice.org.uk/guidance/mpg2/resources) for health professionals using PGDs) * must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (“[The Green Book](https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book)”), and national and local immunisation programmes * must have undertaken training appropriate to this PGD as required by local policy and in line with the [National Minimum Standards and Core Curriculum for Immunisation Training](https://www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners) * must be competent to undertake immunisation and to discuss issues related to immunisation * must be competent in the handling and storage of vaccines, and management of the “cold chain” * must be competent in the recognition and management of anaphylaxis * must have access to the PGD and associated online resources * should fulfil any additional requirements defined by local policy   **THE INDIVIDUAL PRACTITIONER MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.** |
| **Continued training requirements** | Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD).  Practitioners should be constantly alert to any subsequent recommendations from Public Health England and/or NHS England and other sources of medicines information.  Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD. |

1. **Clinical condition or situation to which this PGD applies**

|  |  |
| --- | --- |
| **Clinical condition or situation to which this PGD applies** | Indicated for the active immunisation of patients from 8 weeks of age against *Neisseria meningitidis* group B and for the prevention of secondary cases of meningococcal group B disease, in accordance with the recommendations given in [Chapter 22](https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22) of Immunisation Against Infectious Disease: The Green Book and [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management). |
| **Criteria for inclusion** | Individuals who:   * are aged from 8 weeks up to their second birthday and require routine immunisation * require vaccination for the prevention of secondary cases of Men B, following specific advice from Public Health England Health Protection Teams   Note: Individuals, from 2 years of age, with an underlying medical condition which puts them at increased risk from *Neisseria meningitidis* group B, ie individuals with asplenia, splenic dysfunction or complement disorders (including those on, or due to receive, complement inhibitor treatment ie eculizumab), may require additional ‘routine’ vaccination outside the inclusion criteria for this PGD - see MenB Risk Groups PGD and [Chapter 7](https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7) of “The Green Book. |
| **Criteria for exclusion[[2]](#footnote-3)** | Individuals for whom no valid consent has been received  Individuals who:   * are less than 8 weeks old * are from 2 years of age, unless advised by PHE for the prevention of secondary cases of MenB infection * have had a confirmed anaphylactic reaction to a previous dose of the vaccine * have had a confirmed anaphylactic reaction to any constituent or excipient of the vaccine including kanamycin * require vaccination for occupational health reasons e.g. laboratory workers working with meningococci * have a history of severe (ie anaphylactic) allergy to latex * are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation) |
| **Cautions including any relevant action to be taken**  Continued over page  **Cautions including any relevant action to be taken**  (continued) | Tip cap of the syringe may contain natural rubber latex. For latex allergies other than anaphylactic allergies (eg a history of contact allergy to latex gloves), vaccines supplied in vials or syringes that contain latex can be administered.  Very premature infants (born ≤28 weeks of gestation) who are in hospital should have respiratory monitoring for 48-72 hours when given their first immunisation, particularly those with a previous history of respiratory immaturity. If the child has apnoea, bradycardia or desaturations after the first immunisation, the second immunisation should also be given in hospital, with respiratory monitoring for 48-72 hours.  Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. |
| **Action to be taken if the patient is excluded** | If aged less than 8 weeks 4CMenB is not routinely indicated, advise when the individual can be vaccinated.  If aged from 2 years and not in a clinical risk group or requiring vaccination for the prevention of secondary cases of MenB disease, the individual/parent/carer should be advised that 4CMenB is not indicated. Individuals at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorders (including those on complement inhibitor treatment i.e. eculizumab) should be vaccinated in accordance with the recommended schedules in [Chapter 7](https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7) and [Chapter 22](https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22) of “The Green Book” (see MenB Risk Groups PGD).  Individuals requiring vaccination for occupational health reasons, eg laboratory workers working with meningococci, should be referred to their occupational health service provider for vaccination.  Individuals who have a history of severe (i.e. anaphylactic) allergy to latex should not be administered 4CMenB unless the benefit of vaccination outweighs the risk of an allergic reaction – A Patient Specific Direction (PSD) will be required.  Individuals suffering acute severe febrile illness should postpone immunisation until they have recovered; immunisers should advise when the individual can be vaccinated and ensure another appointment is arranged.  Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual’s clinician as required.  The risk to the individual of not being immunised must be taken into account.  Document the reason for exclusion and any action taken in the individual’s clinical records.  In a GP practice setting, inform or refer to the GP or a prescriber as appropriate. |
| **Action to be taken if the patient or carer declines treatment** | Informed consent, from the individual or a person legally able to act on the person’s behalf, must be obtained for each administration.  Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications of disease.  Document advice given and the decision reached.  In a GP practice setting, inform or refer to the GP as appropriate. |
| **Arrangements for referral for medical advice** | As per local policy |

1. **Description of treatment**

|  |  |
| --- | --- |
| **Name, strength & formulation of drug** | Meningococcal group B Vaccine (rDNA, component, adsorbed), 4CMenB, eg:   * Bexsero®▼suspension for injection, 0.5ml, in a pre-filled syringe |
| **Legal category** | Prescription only medicine (POM) |
| **Black triangle▼** | Bexsero®▼is black triangle, any suspected adverse reactions should be reported via the National Reporting System and Yellow Card Scheme. |
| **Off-label use** | The vaccine schedule differs from the current Bexsero®▼ SPC. However, the national routine schedule is as recommended by the Joint Committee of Vaccination and Immunisation (JCVI) and Public Health England, in line with [Chapter 22](https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22) of “The Green Book” and the vaccine schedule for the prevention of secondary cases of MenB disease (Annex A) is in accordance with the [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management).  Administration by deep subcutaneous injection to patients with a bleeding disorder is off-label administration in line with advice in [Chapter 4](https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4) and [Chapter 22](https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22) of “The Green Book”.  Vaccine should be stored according to the conditions detailed in the [Storage section](#Storage) below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to [PHE Vaccine Incident Guidance](https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors). Where vaccine is assessed in accordance with these guidelines as appropriate for continued use this would constitute off-label administration under this PGD.  Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence. |
| **Route / method of administration**  Continued over page  **Route / method of administration**  (continued) | 4CMenB is given as a 0.5ml dose by intramuscular injection.  In infants and for the routine booster dose, PHE recommend that all doses of 4CMenB be given in the anterolateral aspect of the left thigh, ideally on their own, so that any local reactions can be monitored more accurately. Vaccine may alternatively be administered in the deltoid muscle region of the upper arm in older subjects (from 1 year of age). If another vaccine needs to be administered in the same limb they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual’s records.  The vaccine must not be injected intravenously or intradermally and must not be mixed with other vaccines in the same syringe.  The vaccine must not be given subcutaneously except to individuals with a bleeding disorder when vaccines normally given by an IM route should be given by deep subcutaneous injection to reduce the risk of bleeding (see Green Book [Chapter 4](https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4)).  **Handling of vaccine before administration**  The vaccine is a white opalescent liquid suspension. Upon storage a fine off-white deposit may be observed in the pre-filled syringe containing the suspension. Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension.  The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.  The vaccine’s SPC provides further guidance on administration and is available from the electronic Medicines Compendium website:  [www.medicines.org.uk](http://www.medicines.org.uk) |
| **Dose and frequency of administration** | **Routine Immunisation Schedule**  The national recommendation for infants is for a two dose primary course of 4CMenB, routinely starting at 8 weeks of age, to be administered with an 8 week interval and a booster dose to be administered, usually on or after their first birthday, although it may be administered until 2 years of age.  4CMenB 0.5ml should ideally be given as follows:   * first primary immunisation visit (usually at age 8 weeks) * third primary immunisation visit (usually at age 16 weeks) * booster on or after the first birthday   **Vaccination of eligible children (born on or after 01/07/2015) with uncertain or incomplete immunisation status**  Infants with uncertain or incomplete MenB vaccine history should be vaccinated in accordance with the [vaccination of individuals with uncertain or incomplete immunisation status](https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status) flow chart.  Infants under 1 year of age at presentation who have not completed a 4CMenB primary course should complete two doses at least 8 weeks apart and then continue with the routine schedule (ie a booster on or after their first birthday) ensuring at least an 8 week interval between doses.  Infants born on or after 1 July 2015, who received less than 2 doses of 4CMenB in the first year of life should receive two doses of 4CMenB at least 8 weeks apart in the second year of life (ie between their first and second birthday).  **Prevention of secondary cases of Men B disease**  Vaccination for the prevention of secondary cases of MenB disease should be in accordance with recommendations from the local Public Health England Health Protection Team and informed by the Public Health England [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management).  See [Annex A](#ANNEXA) for a vaccination schedule based on 4CMenB vaccination status. |
| **Duration of treatment** | See dose section above |
| **Quantity to be supplied / administered** | Single dose of 0.5ml per an administration |
| **Supplies**  Continued over page  **Supplies**  (continued) | Centrally purchased vaccines for the national immunisation programme can only be ordered via ImmForm. Vaccines for use for the national immunisation programme are provided free of charge. Vaccines for private prescriptions, occupational health use or travel, are NOT provided free of charge and should be ordered from the manufacturer/wholesalers.  Vaccine for the national immunisation programme should not be used for the prevention of secondary cases of MenB. Vaccine should be ordered from the manufacturer/wholesalers.  Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see [protocol for ordering storage and handling of vaccines](https://www.gov.uk/government/publications/protocol-for-ordering-storing-and-handling-vaccines) and Green Book [Chapter 3](https://www.gov.uk/government/publications/storage-distribution-and-disposal-of-vaccines-the-green-book-chapter-3)). |
| **Storage** | Store at +2°C to +8°C.  Store in original packaging in order to protect from light.  Do not freeze.  In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. Refer to [PHE Vaccine Incident Guidance](https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors). |
| **Disposal** | Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of at the end of a session by sealing in a UN-approved puncture-resistant ‘sharps’ box, according to local authority regulations and guidance in the [technical memorandum 07-01](https://www.gov.uk/government/publications/guidance-on-the-safe-management-of-healthcare-waste): Safe management of healthcare waste (Department of Health, 2013). |
| **Drug interactions** | Immunological response may be diminished in patients receiving immunosuppressant treatment. Vaccination is recommended even if the antibody response may be limited.  4CMenB can be given at the same time as the other vaccines administered as part of the routine childhood immunisation programme. |
| **Identification & management of adverse reactions**  Continued over page  **Identification & management of adverse reactions**  (continued) | The most common local and systemic adverse reactions observed in clinical trials after administration of 4CMenB to infants and children (less than 2 years of age) were tenderness and erythema at the injection site, fever and irritability. Diarrhoea and vomiting, eating disorders, sleepiness, unusual crying, headache, arthralgia and the development of a rash were commonly or very commonly seen in this age group.  Due to the high incidence of fever when primary doses of 4CMenB are administered with other routine immunisations, prophylactic use of paracetamol is recommended by the JCVI for infants receiving their 4CMenB two dose primary immunisation schedule with other routine immunisations. Paracetamol should be administered at the time or shortly after vaccination to reduce the incidence and severity of fever after vaccination. 2.5ml (60mg) of infant paracetamol 120mg/5ml suspension should be given prophylactically every 4-6 hours for three doses. Recent studies have confirmed that prophylactic paracetamol does not affect the immunogenicity of either 4CMenB or other routine vaccines in the infant immunisation schedule.  Paracetamol prophylaxis is not required if the immunisation visit does not include 4CMenB (e.g. the 3-month routine vaccinations) or with the 4CMenB booster after the first birthday (because 4CMenB does not increase the rates of fever at this age). Fever rates in infants receiving 4CMenB alone are similar to the other routine immunisations so paracetamol prophylaxis is not required. See [Patient Advice/Follow-up](#Patientadvice).  In adolescents and adults the most common local and systemic adverse reactions observed were pain at the injection site, malaise and headache.  A detailed list of adverse reactions is available in the vaccine’s SPC, which is available from the electronic Medicines Compendium website: [www.medicines.org.uk](http://www.medicines.org.uk) |
| **Reporting procedure of adverse reactions** | As with all vaccines, healthcare professionals and patients/parents/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: <http://yellowcard.mhra.gov.uk>  Bexsero®▼is black triangle. Therefore, any suspected adverse reactions should be reported via the National Reporting System and Yellow Card Scheme, documented in the patient’s record and the patient’s GP should be informed. |
| **Written information to be given to patient or carer** | Offer marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine.  Immunisation promotional material may be provided as appropriate:   * [Documents relating to the Meningococcal B (MenB) vaccination programme.](https://www.gov.uk/government/collections/meningococcal-b-menb-vaccination-programme) * [Protecting your baby against meningitis and septicaemia caused by meningococcal B bacteria](https://www.gov.uk/government/publications/menb-guidance-for-parents-on-meningitis-and-septicaemia) * [A guide to immunisations for babies up to 13 months of age](https://www.gov.uk/government/publications/a-guide-to-immunisations-for-babies-up-to-13-months-of-age) * [A quick guide to childhood immunisation for the parents of premature babies](https://www.gov.uk/government/publications/a-quick-guide-to-childhood-immunisation-for-the-parents-of-premature-babies)   Available from: [www.gov.uk/government/collections/immunisation](http://www.gov.uk/government/collections/immunisation) |
| **Patient advice / follow up treatment** | 4CMenB is not expected to provide protection against all circulating meningococcal group B strains. Individuals should continue to seek prompt medical attention at the first signs of possible meningitis or septicaemia.  Inform patient/parent/carer of possible side effects and their management.  If appropriate, advise the patient/parent/carer about the use and timing of paracetamol doses to reduce the risk, intensity and duration of fever (see [Identification and management of adverse reactions](#IdentificationOfADRs)).  The patient/parent/carer should be advised to seek medical advice in the event of an adverse reaction or if they are concerned that their infant is unwell at any time.  When applicable, advise the patient/parent/carer when the subsequent vaccine dose is due.  When administration is postponed advise the patient/parent/carer when to return for vaccination. |

|  |  |
| --- | --- |
| **Special considerations / additional information** | Ensure there is immediate access to adrenaline (epinephrine) 1 in 1000 injection and access to a telephone.  Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered. This is to avoid confusing the differential diagnosis of any acute illness by wrongly attributing signs or symptoms to adverse effects of the vaccine.  Vaccination of preterm infants using Bexsero®▼ is indicated (without correction for prematurity) if the infant is clinically stable. As the benefit of vaccination is high in premature and very premature infants, vaccination should not be withheld or delayed (see [Cautions](#Cautions)).  Meningococcal vaccines may be given to pregnant women when clinically indicated. There is no evidence of risk from vaccinating pregnant women or those who are breast-feeding with inactivated bacterial vaccines.  For further information on preventing secondary cases see the Public Health England [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management)**.** |
| **Records** | Record:   * that valid informed consent was given * name of individual, address, date of birth and GP with whom the individual is registered * name of immuniser * name and brand of vaccine * date of administration * dose, form and route of administration of vaccine * quantity administered * batch number and expiry date * anatomical site of vaccination * advice given, including advice given if excluded or declines immunisation * details of any adverse drug reactions and actions taken * supplied via Patient Group Direction (PGD)   Records should be signed and dated (or a password controlled immuniser’s record on e-records).  All records should be clear, legible and contemporaneous.  This information should be recorded in the individual’s GP record. Where vaccine is administered outside the GP setting appropriate health records should be kept and the individual’s GP informed.  The local Child Health Information Systems team (Child Health Records Department) must be notified using the appropriate documentation/pathway as required by any local or contractual arrangement.  A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy. |

1. **Key references**

|  |  |
| --- | --- |
| **Key references**  Continued over page  **Key references**  (continued) | **Meningococcal B Vaccination**   * Immunisation Against Infectious Disease: The Green Book, [Chapter 4](https://www.gov.uk/government/publications/immunisation-procedures-the-green-book-chapter-4), last updated June 2012, [Chapter 7](https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7), last updated 29 September 2016 and [Chapter 22](https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22) last updated 20 September 2016   <https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book>   * Bexsero®▼Summary of Product Characteristics, GlaxoSmithKline UK. Updated 29 September 2017 <http://www.medicines.org.uk/emc/medicine/28407> * NHS public health functions agreement 2017-18, Service specification No. 31, Meningococcal group B (MenB) programme. April 2017   <https://www.england.nhs.uk/publication/public-health-national-service-specifications/>   * Meningococcal B (MenB) vaccination programme. Last updated 26 February 2016.   <https://www.gov.uk/government/collections/meningococcal-b-menb-vaccination-programme>   * Guidance for Public Health Management of Meningococcal Disease in the UK, Public Health England, updated February 2018. Published 13 March 2018   <https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management>   * Vaccination of individuals with uncertain or incomplete immunisation status. Public Health England. Updated 13 November 2017   <https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status>  **General**   * British National Formulary (BNF) and British National Formulary for Children (BNF-C) [www.BNF.org](http://www.BNF.org)   https://bnf.nice.org.uk/drug/meningococcal-group-b-vaccine-rdna-component-adsorbed.html   * Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Department of Health 20 March 2013 <https://www.gov.uk/government/publications/guidance-on-the-safe-management-of-healthcare-waste> * National Minimum Standards and Core Curriculum for Immunisation Training. Published February 2018 <https://www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners> * NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published March 2017. <https://www.nice.org.uk/guidance/mpg2> * NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. January 2014. <https://www.nice.org.uk/guidance/mpg2/resources> * PHE Immunisation Collection <https://www.gov.uk/government/collections/immunisation> * PHE Vaccine Incident Guidance   <https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors>   * Protocol for ordering storage and handling of vaccines. April 2014.   <https://www.gov.uk/government/publications/protocol-for-ordering-storing-and-handling-vaccines> |

1. **Practitioner authorisation sheet**

**MenB PGD v03.00 Valid from: 01/05/2018 Expiry: 30/04/2020**

Before signing this PGD, check that the document has had the necessary authorisations in section two. Without these, this PGD is not lawfully valid.

**Practitioner**

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

|  |  |  |  |
| --- | --- | --- | --- |
| I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct. | | | |
| Name | Designation | Signature | Date |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Authorising manager**

|  |  |  |  |
| --- | --- | --- | --- |
| I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of **INSERT NAME OF ORGANISATION** for the above named health care professionals who have signed the PGD to work under it. | | | |
| Name | Designation | Signature | Date |
|  |  |  |  |

**Note to authorising manager**

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.

**ANNEX A**

**Schedule guidance for secondary prevention of MenB disease**

Vaccination for the prevention of secondary cases of MenB disease should be in accordance with recommendations from the local Public Health England Health Protection Team and informed by the Public Health England [Guidance for Public Health Management of Meningococcal Disease in the UK](https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management). The aim of the response is to give protection as early as possible against MenB strains covered by the vaccine.

|  |  |  |
| --- | --- | --- |
| **Age** | **4CMenB Vaccination Status** | **Schedule for secondary prevention of MenB disease** |
| < 8 weeks old | Unvaccinated | Vaccinate in accordance with the routine vaccination schedule at the appropriate ages |
| ≥ 8 weeks and < 1 year old | Unvaccinated | Give 2 doses eight weeks apart with a booster at 1 year of age |
| 1-10 year-olds | Unvaccinated | Give 2 doses four weeks apart\* |
| >10 years old and adults | Unvaccinated | Give 2 doses four weeks apart |
| < 1 year old | Vaccinated | Continue and complete routine vaccination schedule |
| ≥1 year old | Received only a single dose of 4CMenB in infancy | Give a second dose of MenB providing at least four weeks\* have elapsed since the last dose. A further dose should be given four weeks\* later. |
| ≥1 year old | Completed only primary vaccination with two doses in infancy | Give a single booster dose providing at least four weeks\* have elapsed since the last dose. |
| ≥1 year old | Completed only a single dose in infancy and a booster after first birthday | Give a single dose of MenB providing at least four weeks\* have elapsed since the last dose. |
| ≥1 year old | Fully vaccinated, have received two or more doses in infancy plus a booster after first birthday. | If the final dose was given more than 12 months previously give a single booster dose of MenB vaccine.  If the final dose was given within the past 12 months no further vaccination is needed. |
| ≥1 year old | Partially vaccinated (outside the national programme\*\*), one dose only received after first birthday. | Give a single dose of MenB providing at least four weeks\* have elapsed since the last dose. |
| ≥1 year old | Fully vaccinated (outside the national programme\*\*), two doses received after first birthday. | If the final dose was given more than 12 months previously give a single booster dose of MenB vaccine.  If the final dose was given within the past 12 months no further vaccination is needed. |

\*There is no accelerated immunisation schedule for 4CMenB but the interval between doses for 1-10 year olds should be reduced to four weeks for secondary prevention of MenB disease because of the need for rapid protection.

\*\* This may include individuals with asplenia, splenic dysfunction or complement disorder, who have been previously vaccinated due to being at increased risk of meningococcal disease.

1. This includes any relevant amendments to legislation (eg [2013 No.235](http://www.legislation.gov.uk/uksi/2013/235/contents/made), [2015 No.178](http://www.legislation.gov.uk/nisr/2015/178/contents/made) and [2015 No.323](http://www.legislation.gov.uk/uksi/2015/323/contents/made)). [↑](#footnote-ref-2)
2. Exclusion under this Patient Group Direction does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required [↑](#footnote-ref-3)